Table 4.

Dose reductions for inhibition of HIV-1 by HNG-156 combinations at the EC₅₀ and EC₉₀

Combinationa	EC50 (nM)b for:		DRIc at EC50	EC90 (nM)b for:		DRI at EC90
	Drug alone	Combination		Drug alone	Combination
HNG-156 + sCD4
HNG-156	1,176 ± 237	325 ± 65	3.3 ± 0.7	5,484 ± 1,735	2,155 ± 541	3.2 ± 1.1
sCD4	10.2 ± 1.4	4.2 ± 0.7	2.5 ± 0.3	41.2 ± 8.8	24.0 ± 6.1	1.9 ± 0.3
HNG-156 + MVC
HNG-156	692 ± 61	261 ± 51	3.8 ± 1.2	4,435 ± 568	1,543 ± 320	3.9 ± 1.2
MVC	0.99 ± 0.2	0.25 ± 0.05	4.8 ± 1.3	7.7 ± 1.2	1.5 ± 0.3	5.9 ± 1.3
HNG-156 + TAK
HNG-156	713 ± 131	316 ± 103	2.8 ± 0.4	9,741 ± 3,190	2,099 ± 512	3.4 ± 2.5
TAK	16.8 ± 4.0	6.0 ± 2.0	2.8 ± 0.5	101.8 ± 13.5	31.5 ± 7.7	4.5 ± 0.6
HNG-156 + C34
HNG-156	753 ± 174	298 ± 63	3.0 ± 0.5	3,576 ± 470	1,503 ± 155	2.4 ± 0.2
C34	2.2 ± 0.3	0.60 ± 0.13	4.6 ± 1.2	12.1 ± 1.5	3.0 ± 0.3	4.3 ± 0.7
HNG-156 + CVN
HNG-156	742 ± 90	177 ± 37	6.9 ± 2.0	4,540 ± 498	1,069 ± 181	5.5 ± 1.0
CVN	0.44 ± 0.13	0.11 ± 0.02	7.1 ± 3.1	1.8 ± 0.36	0.66 ± 0.13	3.3 ± 0.7
HNG-156 + GRFT
HNG-156	0.61 ± 0.11	0.15 ± 0.06	3.6 ± 0.3	4,516 ± 1,022	989 ± 220	4.5 ± 1.2
GRFT	0.06 ± 0.03	0.01 ± 0.005	4.5 ± 1.5	0.66 ± 0.10	0.10 ± 0.06	10.9 ± 5.0
HNG-156 + 2G12
HNG-156	652 ± 120	211 ± 19	3.1 ± 0.3	3,524 ± 1,193	1,147 ± 274	2.9 ± 0.3
2G12	1.3 ± 0.22	0.28 ± 0.02	4.9 ± 1.3	11.2 ± 4.4	1.5 ± 0.33	10.0 ± 6.4
HNG-156 + TDF
HNG-156	707 ± 112	287 ± 78	3.2 ± 1.0	7,110 ± 2,191	1,192 ± 139	6.7 ± 2.8
TDF	6,824 ± 448	2,530 ± 689	3.6 ± 1.2	43,679 ± 19,239	10,489 ± 1,219	3.8 ± 1.2

^aMVC, maraviroc; TAK, TAK-79; CVN, cyanovirin-N; GRFT, griffithsin; TDF, tenofovir.

^bDetermined on the basis of infection of HOS.CD4.CCR5 target cells by recombinant luciferase-expressing HIV-1. See Table 1, footnote a, for data treatment.

^cDose reduction index (DRI) values for each inhibitor within the combination were calculated using CalcuSyn software.